Evaluation of the Effect of Ultrashort-Acting Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)

Trial Profile

Evaluation of the Effect of Ultrashort-Acting Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2014

At a glance

  • Drugs Clevidipine (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms VELOCITY
  • Sponsors The Medicines Company
  • Most Recent Events

    • 27 Aug 2008 Results published in the Annals of Emergency Medicine, as reported by a The Medicines Company media release.
    • 02 Feb 2007 Status changed from recruiting to completed.
    • 13 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top